Perturbation type | Gene | Citation | Cancer type | Gene-disease relation |
---|---|---|---|---|
Top gains | LONRF3 (Isoform switch) | 24486590 | Urothelial carcinoma | Array DNA copy-number data from patients with metastatic urothelial carcinoma |
Top gains | RNF146 (Isoform switch) | 22228636 | Urothelial carcinoma | Expression profiling of high-risk urothelial carcinoma of the urinary bladder |
Top gains | SH3BP2 (Isoform switch) | 9299232 | Bladder cancer | Is located within a common region of deletion at 4p16.3 Involved in bladder cancer |
Top losses | GNAQ (Isoform switch) | 25921176 | Bladder cancer | Down-regulated in metastatic advanced Egyptian bladder cancer |
Top gains | BCAN | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | CATSPER1 | 27716384 | BLCA | Significantly altered expression in bladder cancer. |
Top gains | FOXD4 | 22932667 | BLCA | A region of high-level amplification at 9p24.3 (FOXD4-DMRT2) was present in one tumor. |
Top gains | FOXH1 | 21063397 | BLCA | One of frequently upregulated genes on chromosome 8q24.3 in bladder cancer cell lines. |
Top gains | GUCY1A2 | 29854840 | BLCA | Up-regulated in bladder cancer. |
Top gains | HIST1H2AB | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | HIST1H2AE | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | HIST1H2BJ | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | HIST2H2AC | 30089500 | BLCA | Differentially expressed in tumor samples compared to normal samples. |
Top gains | HMGA2 | 24571540 | BLCA | Expression of HMGA2; loss of E-cadherin and expression of vimentin are all significantly correlated with bladder cancer grade and stage. |
Top gains | KCNJ10 | 30089500 | BLCA | Differentially expressed in tumor samples compared to normal samples |
Top gains | LRRC46 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | MAST1 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | OTX1 | 28049011 | BLCA | Potential urinary biomarker for primary nonmuscle invasive bladder cancer. |
Top gains | SLX4IP | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top gains | TMEM52B | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific gains | DLG1 | 27582092 | BLCA:metastatic | Mutation in DLG1 is associated with metastatic urothelial carcinoma. |
Top cancer-specific gains | DLG3 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific gains | DLG4 | 29739919 | BLCA | DLG4 is hypermethylated/low-expressed in bladder cancer samples. |
Top cancer-specific gains | ERBIN | 25629698 | UTUC(upper urinary tract urothelial cancer) | Involved in urothelial carcinogenesis. |
Top cancer-specific gains | GUCY1A2 | 29854840 | BLCA | Up-regulated in bladder cancer samples. |
Top cancer-specific gains | GUCY1B1 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific gains | HSP90AA1 | 27034531 | BLCA | The smoking-related protein HSP90AA1 and DNA methylation of ECT2 mediate metastasis of bladder cancer. |
Top cancer-specific gains | HSPA4 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific gains | LIN7A | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific gains | SNTA1 | 24969694 | BLCA | Differentially expressed in bladder cancer cell lines. |
Top cancer-specific gains | STUB1 | 27451077 | BLCA | Down-regulated in high grade NMI (non-muscle invasive) bladder cancer. |
Top losses | ACTA1 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | ADCYAP1 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | ADRA1D | 29655996 | BLCA | ADRA1D is significantly correlated with lymph node status in bladder cancer patients. |
Top losses | APP | 30021247 | BLCA | Amyloid precursor protein is upregulated in bladder cancer; and might be closely associated with bladder cancer cell growth and survival. |
Top losses | ASB16 | 28156048 | BLCA | ASB16 belongs to proteins identified with high confidence level in Tn‐negative; blood group A negative; STn‐positive bladder cancer tumor samples recovered from formalin‐fixed paraffin embedded tissues. |
Top losses | AURKC | 29058301 | BLCA:transitional | Differentially expressed in transitional bladder cancer samples compared to normal samples |
Top losses | AVPR2 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | BEX1 | 22228636:21421225 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. : Involved in urothelial maturation. |
Top losses | BMX | 21408190 | BLCA | ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. |
Top losses | CLEC4G | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | CMTM5 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | EFHC2 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | ENPP6 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | FAM124A | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | FOXD3 | 28665070 | BLCA | Down-regulated in non-muscle invasive high-grade urothelial carcinoma of the bladder. |
Top losses | GPM6A | 29200870 | BLCA | Potential target for miRNA biomarkers in bladder cancer. |
Top losses | GRIN2A | 24469795 | BLCA | Amplification of GRIN2A in a subset of TCC-UB representing a potential therapeutic target. |
Top losses | ISL1 | 26332997 | BLCA | ISL1 showed significantly higher mean methylation in recurrent and progressive tumors compared to non-recurrent tumors. |
Top losses | KCNA3 | 20025600 | BLCA | Differentially expressed in tumor samples compared to normal samples. |
Top losses | KCNA5 | 20025600 | BLCA | Differentially expressed in tumor samples compared to normal samples. |
Top losses | MEFV | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | MYH7B | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | P2RY12 | 30778022 | BLCA | P2RY1 is a target gene of miR-34b-3p; which have a negative regulatory effect on multidrug resistance of bladder cancer |
Top losses | PRPH | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | RUNX1T1 | 29963227 | NMIBC(non-muscle invasive bladder cancer):MIBC ( muscle invasive bladder cancer) | Differentially regulated by miR-5701 in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) cells |
Top losses | RXRG | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | SCN2B | 21116856 | BLCA | Differentially expressed in bladder cancer cell lines |
Top losses | SOX5 | 30983072 | BLCA | circDOCK1 affected the progression of BC via modulation of circDOCK1/hsa-miR-132-3p/Sox5 pathway both in vitro and in vivo. |
Top losses | STX1B | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top losses | ZBTB20 | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific losses | KCNA3 | 20025600 | BLCA | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific losses | FAM124A | 22228636 | BLCA | Differentially expressed in a high-risk population of patients who underwent radical cystectomy. |
Top cancer-specific losses | PIPOX | 26802582 | BLCA | Differential expression in tumor samples compared to normal samples |
SMGs within edgetic gains or losses | ATM | 28138703 | BLCA | ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer. |
SMGs within edgetic gains or losses | CDKN2A | 30258198 | MIBC(muscle invasive bladder cancer) | CDKN2A RNA expression-based risk stratification of MIBC allows the identification of a CDKN2A high poor prognosis group with low expression of drug target genes. |
SMGs within edgetic gains or losses | CTNNB1 | 30015971 | BLCA | Human bladder cancer SW780 cells were identified as having high expression of beta‑catenin (CTNNB1). |
SMGs within edgetic gains or losses | CUL1 | 27312089 | BLCA | CUL1 was dramatically overexpressed in high-grade urothelial carcinoma (UC) tissues compared with low-grade UC tissues. |
SMGs within edgetic gains or losses | EP300 | 21935574 | BLCA | p300 (EP300) expression was reduced in doxorubicin-resistant bladder cancer cells and in response to doxorubicin exposure. |
SMGs within edgetic gains or losses | ERBB3 | 29434875 | BLCA | The high soluble HER3 (ERBB3) levels are associated with improved survival rates in patients with bladder cancer; and that soluble HER3 inhibits bladder cancer cell growth and migration. |
SMGs within edgetic gains or losses | FBXW7 | 28772241 | BLCA | The novel overexpressed p65-initiated PTEN/FBW7(FBXW7)/RhoGDIalpha migration regulatory axis provides new insights into the mechanisms of the underlying nature of p65 in regulation of BC cell motility. |
SMGs within edgetic gains or losses | KRAS | 24058630 | BLCA | Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. |
SMGs within edgetic gains or losses | MDM4 | 27798881 | MIBC(muscle invasive bladder cancer) | The low MDM4 expression were associated with recurrence-free and cancer-specific survival in patients with MIBC. |
SMGs within edgetic gains or losses | PIK3CA | 30593515 | HG-UTUC(high-grade upper tract urothelial cancers) | Alterations in PIK3CAcorrelated with worse overall survival in HG-UTUC and occurred concurrently. |
SMGs within edgetic gains or losses | PSIP1 | 17363574 | BLCA | PSIP1(LEDGF) expression is increased in human breast and bladder carcinomas correlating with that of Hsp70-2 in invasive bladder cancer. |
SMGs within edgetic gains or losses | PTEN | 30575901:30719818 | BLCA | MiR-103/107 regulates cell proliferation and PI3K/AKT signaling partially through PTEN dependent mechanism. Nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling. |
SMGs within edgetic gains or losses | RB1 | 24476821 | BLCA | Recurrent mutation in RB1. |
SMGs within edgetic gains or losses | RBM10 | 30852032 | BLCA | The loss of RBM10 expression is observed across all bladder tumor stages and grades; suggesting that it is an early event in tumor progression. |
SMGs within edgetic gains or losses | SPTAN1 | 23452234 | BLCA | The significant expression in the group of patients without recurrence. |
SMGs within edgetic gains or losses | TP53 | 28760909 | BLCA | Deleterious alterations in TP53. |
SMGs within edgetic gains or losses | TSC1 | 28760909 | BLCA | Truncating mutations in TSC1. |
To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button